Leerink Partnrs Has Pessimistic View of AQST Q4 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Research analysts at Leerink Partnrs dropped their Q4 2025 EPS estimates for shares of Aquestive Therapeutics in a research report issued on Monday, November 10th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings per share of ($0.16) for the quarter, down from their prior forecast of ($0.15). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. Leerink Partnrs also issued estimates for Aquestive Therapeutics’ FY2026 earnings at ($0.50) EPS, FY2027 earnings at ($0.33) EPS and FY2028 earnings at ($0.01) EPS.

Several other equities analysts have also recently issued reports on the company. Lifesci Capital upgraded Aquestive Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 3rd. Wall Street Zen upgraded Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. JMP Securities upped their price objective on Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a report on Thursday, October 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, October 8th. Finally, Citigroup restated an “outperform” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $10.00.

Aquestive Therapeutics Trading Down 2.2%

Shares of Aquestive Therapeutics stock traded down $0.13 on Thursday, reaching $5.46. 1,200,243 shares of the stock were exchanged, compared to its average volume of 1,988,658. The firm has a market capitalization of $665.51 million, a PE ratio of -7.68 and a beta of 1.79. Aquestive Therapeutics has a 1-year low of $2.12 and a 1-year high of $7.55. The business has a fifty day moving average price of $5.99 and a two-hundred day moving average price of $4.34.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The business had revenue of $12.81 million for the quarter, compared to the consensus estimate of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Aquestive Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AQST. Vanguard Group Inc. grew its stake in Aquestive Therapeutics by 30.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock worth $31,651,000 after acquiring an additional 1,333,627 shares during the period. Commonwealth Equity Services LLC acquired a new stake in shares of Aquestive Therapeutics during the third quarter worth $5,918,000. Pale Fire Capital SE boosted its holdings in shares of Aquestive Therapeutics by 154.1% during the first quarter. Pale Fire Capital SE now owns 1,335,684 shares of the company’s stock worth $3,873,000 after purchasing an additional 809,928 shares during the last quarter. Federated Hermes Inc. purchased a new stake in shares of Aquestive Therapeutics in the third quarter valued at $4,381,000. Finally, Aberdeen Group plc acquired a new position in Aquestive Therapeutics in the third quarter valued at $3,494,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Insider Buying and Selling

In related news, insider Peter E. Boyd sold 10,000 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $7.00, for a total value of $70,000.00. Following the completion of the transaction, the insider owned 268,323 shares of the company’s stock, valued at approximately $1,878,261. The trade was a 3.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Carl N. Kraus sold 20,272 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $7.00, for a total transaction of $141,904.00. Following the sale, the insider directly owned 282,475 shares in the company, valued at $1,977,325. This represents a 6.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 276,770 shares of company stock valued at $1,692,203 over the last three months. Insiders own 8.35% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.